BioCardia Granted Patent for Interventional Catheter-Based Therapies

The U.S. Patent and Trademark Office has issued BioCardia Inc. a patent for its multi-directional steerable catheter technology.

The patent, according to the company, further protects the Helix Biotherapeutic Delivery System and enhances its biotherapeutic delivery capabilities. “We continue to believe that delivery is critically important for successful biotherapeutic treatment,” said BioCardia CEO Peter Altman, Ph.D. “By enabling best-in-class full solutions for the physician in treating patients, we maximize the probability of our therapeutics improving the lives of millions with heart disease. We expect this well patented technology to enhance physician control for our biotherapeutic programs, partnered biotherapeutic programs, transseptal cardiac interventions, and other interventional therapies throughout the body.”
 
This patent covers a multidirectional steerable catheter with uniform bending rigidity and is expected to significantly enhance physician control by preventing “whip,” the tendency of steerable catheters to build up torque and jump to another location. The patented technology is incorporated in the company’s U.S. Food and Drug Administration-cleared Morph DNA guide used in biotherapeutic delivery procedures and AVANCE steerable introducer used in transseptal access procedures. The advances are also expected to strengthen the company’s clinical stage biotherapeutic programs in heart failure and chronic myocardial ischemia. 
 
BioCardia estimates the cardiac cell therapy market for its current investigational programs at approximately 1.6 million patients in the United States,¹ each treatment of which has potential to utilize the approved Morph DNA guide product. The transseptal access market which the company’s approved AVANCE product addresses is estimated at $490 million and is expected to increase at a compound annual growth rate (CAGR) of 10.4 percent from 2017 to 2024² with an acquisition this month of a market leader for $1.75 billion.³
 
BioCardia Inc.,  headquartered in San Carlos, Calif., develops two biotherapeutic platforms—the CardiAMP autologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogenic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases. 

References 
¹ BioCardia Corporate Presentation, 05295-N (MKT) 2021 Q3.
² Persistence Market Research (2017). “Transseptal Access Systems Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025).” New York, NY. Persistence Market Research Pvt. Ltd.
³ OCT 6, 2021 Boston Scientific Announces Agreement to Acquire Baylis Medical Company Inc. Acquisition to add new left heart access platforms to electrophysiology and structural heart portfolios.